Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $78 price target The company’s lead asset, TTI-101, which is being assessed in the Phase 2 REVERT-IPF trial with data in Q4, is positioned to drive broad improvement with an optimal profile, the analyst tells investors in a research note. The firm says the drug is a “differentiated” STAT3 inhibitor small molecule with non-covalent bonding uniquely positioning it to specifically target canonical nuclear function with no mitochondrial effect.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Tvardi Therapeutics Updates Corporate Presentation on Therapies
- Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks
- Tvardi Therapeutics files to sell 2.08M shares of common stock for holders
- Buy Rating for Tvardi Therapeutics Driven by Promising Phase 2 Trial Results and Growth Potential
- Tvardi Therapeutics completes enrollment in TTI-101 trial